@article{3002754,
    title = "EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis",
    author = "Roberts, G. and Pfaar, O. and Akdis, C.A. and Ansotegui, I.J. and Durham, S.R. and Gerth van Wijk, R. and Halken, S. and Larenas-Linnemann, D. and Pawankar, R. and Pitsios, C. and Sheikh, A. and Worm, M. and Arasi, S. and Calderon, M.A. and Cingi, C. and Dhami, S. and Fauquert, J.L. and Hamelmann, E. and Hellings, P. and Jacobsen, L. and Knol, E.F. and Lin, S.Y. and Maggina, P. and Mösges, R. and Oude Elberink, J.N.G. and Pajno, G.B. and Pastorello, E.A. and Penagos, M. and Rotiroti, G. and Schmidt-Weber, C.B. and Timmermans, F. and Tsilochristou, O. and Varga, E.-M. and Wilkinson, J.N. and Williams, A. and Zhang, L. and Agache, I. and Angier, E. and Fernandez-Rivas, M. and Jutel, M. and Lau, S. and van Ree, R. and Ryan, D. and Sturm, G.J. and Muraro, A.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2018",
    volume = "73",
    number = "4",
    pages = "765-798",
    publisher = "Wiley-Blackwell Publishing Ltd",
    doi = "10.1111/all.13317",
    keywords = "allergen;  beta adrenergic receptor blocking agent;  grass pollen extract;  histamine H1 receptor antagonist;  pollen extract, abdominal pain;  allergic conjunctivitis;  allergic rhinoconjunctivitis;  allergic rhinoconjunctivitis;  anaphylaxis;  Article;  clinical evaluation;  conflict of interest;  consensus;  cost effectiveness analysis;  cost utility analysis;  desensitization;  disease severity;  drug efficacy;  drug safety;  dysesthesia;  epidemiological data;  evidence based medicine;  grass;  human;  long term care;  medication compliance;  meta analysis;  patient education;  perennial rhinitis;  pollen allergy;  practice guideline;  pregnancy outcome;  preventive medicine;  priority journal;  prospective study;  pruritus;  quality of life;  rhinoconjunctivitis;  stakeholder engagement;  subcutaneous immunotherapy;  sublingual immunotherapy;  symptom;  systematic review;  treatment contraindication;  treatment duration;  allergic conjunctivitis;  allergic rhinitis;  desensitization;  practice guideline;  procedures;  standards, Conjunctivitis, Allergic;  Desensitization, Immunologic;  Humans;  Rhinitis, Allergic",
    abstract = "Allergic rhinoconjunctivitis (AR) is an allergic disorder of the nose and eyes affecting about a fifth of the general population. Symptoms of AR can be controlled with allergen avoidance measures and pharmacotherapy. However, many patients continue to have ongoing symptoms and an impaired quality of life; pharmacotherapy may also induce some side-effects. Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on AIT for AR and is part of the EAACI presidential project “EAACI Guidelines on Allergen Immunotherapy.” It aims to provide evidence-based clinical recommendations and has been informed by a formal systematic review and meta-analysis. Its generation has followed the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included involvement of the full range of stakeholders. In general, broad evidence for the clinical efficacy of AIT for AR exists but a product-specific evaluation of evidence is recommended. In general, SCIT and SLIT are recommended for both seasonal and perennial AR for its short-term benefit. The strongest evidence for long-term benefit is documented for grass AIT (especially for the grass tablets) where long-term benefit is seen. To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Many gaps in the evidence base exist, particularly around long-term benefit and use in children. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd."
}